Ab­b­Vie drops Cy­tomX part­ner­ship, leav­ing PhII pro­gram in the air

Ab­b­Vie is wind­ing down its col­lab­o­ra­tion with Cy­tomX sev­en years af­ter first em­bark­ing on a search for con­di­tion­al­ly ac­ti­vat­ed can­cer im­munother­a­py pro­grams.

Cy­tomX will be …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER